← Back to headlines
Piper Sandler Rates Regeneron (REGN) Overweight on Oncology Growth
Piper Sandler has rated Regeneron (REGN) as 'Overweight,' highlighting its growth in the oncology sector.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
